Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial.

Eduardo RamacciottiLeandro Barile AgatiGiuliano Giova VolpianiKaren Falcão BritoCamilla Moreira RibeiroValéria Cristina Resende AguiarLorenzo Storino RamacciottiAlexia PaganottiFelipe Menegueti PereiraRoberto Augusto CaffaroAlexandre FioranelliRogério KrakauerHeron Rhydan Saad RachedNelson WoloskerSonia S AnandJohn W EikelboomRenato Delascio Lopes

Published in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2022)

The COMPASS CLAUDICATION trial will provide high-quality evidence regarding the effect of the combination of rivaroxaban and aspirin on claudication distance in patients with peripheral arterial disease.

Keyphrases

low dose
peripheral artery disease
cardiovascular events
antiplatelet therapy
venous thromboembolism
atrial fibrillation
phase iii
study protocol
clinical trial
pulmonary embolism
phase ii
anti inflammatory drugs
randomized controlled trial
acute coronary syndrome
high intensity